Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic CancerMark J. Truty, Axel Grothey, Michael L. Kendrick et al.|Annals of Surgery|2019Cited by 445
Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic CancerRoberto Alva‐Ruiz, Mark J. Truty, Lindsey A. Gregory et al.|Annals of Surgical Oncology|2021Cited by 68
FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic AdenocarcinomaAmro M. Abdelrahman, Mark J. Truty, Ajit H. Goenka et al.|Journal of the National Comprehensive Cancer Network|2022Cited by 59
A Curative-Intent Trimodality Approach for Isolated Abdominal Nodal Metastases in Metastatic Colorectal Cancer: Update of a Single-Institutional ExperienceBenny Johnson, Axel Grothey, Zhaohui Jin et al.|The Oncologist|2018Cited by 23
Predicting Adverse Pathologic Features and Clinical Outcomes of Resectable Pancreas Cancer With Preoperative CA 19-9Roman O. Kowalchuk, Kenneth W. Merrell, Scott C. Lester et al.|Frontiers in Oncology|2021Cited by 12